Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
Phase II Randomized Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide (AC) in Axillary Node-Positive Breast Cancer
Status: Enrolling
Updated:  8/18/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
Phase II Randomized Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide (AC) in Axillary Node-Positive Breast Cancer
Status: Enrolling
Updated: 8/18/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors
Status: Enrolling
Updated:  8/19/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors
Status: Enrolling
Updated: 8/19/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors
Status: Enrolling
Updated:  8/19/2015
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors
Status: Enrolling
Updated: 8/19/2015
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Resistance Training in Lung Cancer Patients on Chemotherapy
Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Status: Enrolling
Updated:  8/19/2015
Leo Jenkins Cancer Center
mi
from
Greenville, NC
Resistance Training in Lung Cancer Patients on Chemotherapy
Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Status: Enrolling
Updated: 8/19/2015
Leo Jenkins Cancer Center
mi
from
Greenville, NC
Click here to add this to my saved trials
ABC294640 in Treating Patients With Advanced Solid Tumors
A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/19/2015
Medical University of South Carolina
mi
from
Charleston, SC
ABC294640 in Treating Patients With Advanced Solid Tumors
A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/19/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated:  8/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status: Enrolling
Updated: 8/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated:  8/19/2015
UCLA School of Medicine, Center for Health Sciences
mi
from
Los Angeles, CA
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated: 8/19/2015
UCLA School of Medicine, Center for Health Sciences
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated:  8/19/2015
Ucsf Division Of Hematology And Oncology
mi
from
San Francisco, CA
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated: 8/19/2015
Ucsf Division Of Hematology And Oncology
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated:  8/19/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated: 8/19/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated:  8/19/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated: 8/19/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated:  8/19/2015
Weill-Cornell Medical College
mi
from
New York, NY
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status: Enrolling
Updated: 8/19/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  8/19/2015
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 8/19/2015
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  8/19/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 8/19/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
A Randomized Phase II Study of Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy for Patients With Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  8/19/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
A Randomized Phase II Study of Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy for Patients With Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 8/19/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
Status: Enrolling
Updated:  8/20/2015
Texas Children's Hospital
mi
from
Houston, TX
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
Status: Enrolling
Updated: 8/20/2015
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
The Institute for Drug Development
mi
from
San Antonio, TX
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
The Institute for Drug Development
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
South Texas Accelerated
mi
from
San Antonio, TX
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
South Texas Accelerated
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Phase I Trial Of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in Patients With Locoregionally Advanced Head and Neck Carcinoma
Status: Enrolling
Updated:  8/21/2015
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Phase I Trial Of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in Patients With Locoregionally Advanced Head and Neck Carcinoma
Status: Enrolling
Updated: 8/21/2015
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
San Francisco, CA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Rockville, MD
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Boston, MA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
New Brunswick, NJ
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/21/2015
Clinical Research Facility
mi
from
Nashville, TN
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/21/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
Status: Enrolling
Updated:  8/21/2015
Parexel
mi
from
Baltimore, MD
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
Status: Enrolling
Updated: 8/21/2015
Parexel
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
Status: Enrolling
Updated:  8/21/2015
Parexel
mi
from
Baltimore, MD
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
Status: Enrolling
Updated: 8/21/2015
Parexel
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (1.8 mg/mL Rolapitant IV Solution) on the Pharmacokinetics of Digoxin (P-gp); Sulfasalazine (BCRP); and the Cooperstown Cocktail (Midazolam [CYP3A4], Omeprazole [CYP2C19], Warfarin [CYP2C9], Caffeine [CYP1A2], and Dextromethorphan [CYP2D6]) in Healthy Subjects
Status: Enrolling
Updated:  8/21/2015
Parexel Early Phase Unit
mi
from
Baltimor, MD
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (1.8 mg/mL Rolapitant IV Solution) on the Pharmacokinetics of Digoxin (P-gp); Sulfasalazine (BCRP); and the Cooperstown Cocktail (Midazolam [CYP3A4], Omeprazole [CYP2C19], Warfarin [CYP2C9], Caffeine [CYP1A2], and Dextromethorphan [CYP2D6]) in Healthy Subjects
Status: Enrolling
Updated: 8/21/2015
Parexel Early Phase Unit
mi
from
Baltimor, MD
Click here to add this to my saved trials
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  8/21/2015
Lake/University Ireland Cancer Center
mi
from
Cleveland, OH
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 8/21/2015
Lake/University Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  8/21/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 8/21/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  8/21/2015
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 8/21/2015
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  8/21/2015
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 8/21/2015
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Status: Enrolling
Updated:  8/21/2015
University of Utah
mi
from
Salt Lake City, UT
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Status: Enrolling
Updated: 8/21/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging
A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors
Status: Enrolling
Updated:  8/24/2015
Washington University
mi
from
St Louis, MO
Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging
A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors
Status: Enrolling
Updated: 8/24/2015
Washington University
mi
from
St Louis, MO
Click here to add this to my saved trials
PET/CT Evaluation of Treatment Response in Breast Cancer
Positron Emission Tomography (PET)-Computed Tomography (CT) PET/CT Evaluation of Treatment Response in Breast Cancer
Status: Enrolling
Updated:  8/24/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
PET/CT Evaluation of Treatment Response in Breast Cancer
Positron Emission Tomography (PET)-Computed Tomography (CT) PET/CT Evaluation of Treatment Response in Breast Cancer
Status: Enrolling
Updated: 8/24/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage I-IV Breast Cancer
Status: Enrolling
Updated:  8/24/2015
University of Virginia Health System
mi
from
Charlottesville, VA
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage I-IV Breast Cancer
Status: Enrolling
Updated: 8/24/2015
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT
Status: Enrolling
Updated:  8/24/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT
Status: Enrolling
Updated: 8/24/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated:  8/25/2015
1220.48.0008 Boehringer Ingelheim Investigational Site
mi
from
Bakersfield, CA
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated: 8/25/2015
1220.48.0008 Boehringer Ingelheim Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated:  8/25/2015
1199.14.1164 Boehringer Ingelheim Investigational Site
mi
from
Fullerton, CA
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated: 8/25/2015
1199.14.1164 Boehringer Ingelheim Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated:  8/25/2015
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated: 8/25/2015
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated:  8/25/2015
1200.75.10103 Boehringer Ingelheim Investigational Site
mi
from
Santa Barbara, CA
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated: 8/25/2015
1200.75.10103 Boehringer Ingelheim Investigational Site
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated:  8/25/2015
1199.14.1256 Boehringer Ingelheim Investigational Site
mi
from
Lake Success, NY
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy
Status: Enrolling
Updated: 8/25/2015
1199.14.1256 Boehringer Ingelheim Investigational Site
mi
from
Lake Success, NY
Click here to add this to my saved trials